SupplementRationale for the Radiation Therapy Oncology Group Study RTOG P-0014Kenneth J PientaHoward M SandlerProstate cancerChemotherapyAndrogen ablationClinical trialsHormone-refractory disease
SupplementDocetaxel for the Treatment of Hormone-Refractory Prostate CancerDaniel P PetrylakChemotherapyProstate-specific antigenDocetaxelHormone-refractory prostate cancerMicrotubule
SupplementInitial Experience with Single-Agent Docetaxel as Neoadjuvant Therapy in Men with Locally Advanced Prostate CancerRobert DreicerEric A KleinLocally advanced prostate cancerRadical prostatectomyNeoadjuvant
SupplementBiochemical (Prostate-Specific Antigen) Relapse: An Oncologist's PerspectiveMary-Ellen TaplinProstate cancerProstate-specific antigenAdjuvantBiochemical relapse
SupplementCaP CURE Initiatives and ProjectsHoward R SouleProstate cancerProstate-specific antigenCaP CURE
SupplementA Multidisciplinary Approach to the Management of Hormone-Refractory Prostate CancerSamir S TanejaProstate cancerAndrogen-insensitiveHormone-refractoryMultidisciplinary
SupplementThe Role of the Urologist in Treating Patients with Hormone-Refractory Prostate CancerE David CrawfordChemotherapyHormone-refractory prostate cancerTrainingUrologistsReimbursement
SupplementA Multi-Institutional Pilot Study of Adjuvant Docetaxel for Patients with Prostate Cancer at High Risk for Relapse After Radical ProstatectomyMario A EisenbergerHormone-refractory prostate cancerAdjuvant chemotherapyRadical
SupplementE-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent Nonmetastatic Prostate Cancer...Michael CarducciRobert DreicerProstate cancerDocetaxelEstramustineKetoconazole